keyword
MENU ▼
Read by QxMD icon Read
search

EBMT

keyword
https://www.readbyqxmd.com/read/29748438/outcomes-of-hematopoietic-stem-cell-transplantation-from-unmanipulated-haploidentical-versus-matched-sibling-donor-in-patients-with-acute-myeloid-leukemia-in-first-complete-remission-with-intermediate-or-high-risk-cytogenetics-a-study-from-the-acute-leukemia
#1
Dalila Salvatore, Myriam Labopin, Annalisa Ruggeri, Giorgia Battipaglia, Ardeshir Ghavamzadeh, Fabio Ciceri, Didier Blaise, William Arcese, Gerard Socié, Jean Henri Bourhis, Mariateresa Van Lint, Benedetto Bruno, Anne Huynh, Stella Santarone, Eric Deconinck, Mohamad Mohty, Arnon Nagler
Allogeneic hematopoietic stem cell transplantation is the optimal care for patients with high-risk or intermediate acute myeloid leukemia. In patients lacking matched sibling donor, haploidentical donors are an option. We compared outcomes of unmanipulated haploidentical to matched sibling donor transplant in acute myeloid leukemia patients in first complete remission. Included were int- and high-risk acute myeloid leukemia in first complete remission undergoing haploidentical and matched sibling donor transplant from 2007-2015 and reported to the ALWP of the EBMT...
May 10, 2018: Haematologica
https://www.readbyqxmd.com/read/29728701/ibrutinib-for-bridging-to-allogeneic-hematopoietic-cell-transplantation-in-patients-with-chronic-lymphocytic-leukemia-or-mantle-cell-lymphoma-a-study-by-the-ebmt-chronic-malignancies-and-lymphoma-working-parties
#2
Peter Dreger, Mauricette Michallet, Paul Bosman, Sascha Dietrich, Mohamad Sobh, Ariane Boumendil, Arnon Nagler, Christof Scheid, Jan Cornelissen, Dietger Niederwieser, Lutz Müller, Elizabeth Vandenberghe, Ilaria Scortechini, Helene Schoemans, Niels S Andersen, Jürgen Finke, Domenico Russo, Per Ljungman, Jakob Passweg, Michel van Gelder, Nadira Durakovic, Helene Labussiere-Wallet, Tobias Berg, Gerald Wulf, Wolfgang Bethge, Donald Bunjes, Stefan Stilgenbauer, Maria Elisa Canepari, Michel Schaap, Christopher P Fox, Nicolaus Kröger, Silvia Montoto, Johannes Schetelig
The aim of this retrospective study was to investigate the safety and efficacy of allogeneic hematopoietic cell transplantation (alloHCT) in patients pre-treated with ibrutinib. Eligible were patients aged >18 years allotransplanted for chronic lymphocytic leukemia (CLL) or mantle cell lymphoma (MCL) after prior exposure to ibrutinib who were registered with the EBMT registry. Seventy patients (CLL 48, MCL 22) were included. At the time of alloHCT, 73% of the patients were ibrutinib responsive. All patients except one engrafted, and acute GVHD grade 2-4 (3-4) was observed in 49% (12%) of 68 evaluable patients...
May 4, 2018: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/29720705/recommendations-from-the-european-society-for-blood-and-marrow-transplantation-ebmt-for-a-curriculum-in-hematopoietic-cell-transplantation
#3
Mohamad Mohty, Rafael F Duarte, Jurgen Kuball, Peter Bader, Grzegorz W Basak, Chiara Bonini, Enric Carreras, Christian Chabannon, Carlo Dufour, Andrew Gennery, Arjan Lankester, Francesco Lanza, Per Ljungman, Silvia Montoto, Arnon Nagler, John A Snowden, Jan Styczynski, Anna Sureda, Nicolaus Kröger
Hematopoietic cell transplantation (HCT) is increasingly used worldwide. This treatment approach is complex and requires specific knowledge and training. The European Society for Blood and Marrow Transplantation (EBMT) identified the need for a set of international recommendations for the clinical training of physicians to qualify them as being competent in performing HCT procedures as well as novel cellular immune therapies and taking care of such patients. The goal is to implement an EBMT HCT-focused global curriculum (EBMT-GC) that can serve as a tool for the development of the HCT sub-specialty worldwide...
May 2, 2018: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/29679774/comparable-results-of-autologous-and-allogeneic-haematopoietic-stem-cell-transplantation-for-adults-with-philadelphia-positive-acute-lymphoblastic-leukaemia-in-first-complete-molecular-remission-an-analysis-by-the-acute-leukemia-working-party-of-the-ebmt
#4
Sebastian Giebel, Myriam Labopin, Michael Potter, Xavier Poiré, Henrik Sengeloev, Gerard Socié, Anne Huynh, Boris V Afanasyev, Urs Schanz, Olle Ringden, Peter Kalhs, Dietrich W Beelen, Antonio M Campos, Tamás Masszi, Jonathan Canaani, Mohamad Mohty, Arnon Nagler
BACKGROUND: Allogeneic haematopoietic stem cell transplantation (alloHSCT) is considered a standard treatment for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia (Ph+ ALL) achieving complete remission after induction containing tyrosine kinase inhibitors (TKIs). METHODS: We retrospectively compared results of myeloablative alloHSCT from either matched sibling donor (MSD) or unrelated donor (URD) with autologous (auto) HSCT for adults with Ph+ ALL in molecular remission, treated between 2007 and 2014...
June 2018: European Journal of Cancer
https://www.readbyqxmd.com/read/29678639/transplant-outcomes-for-secondary-acute-myeloid-leukemia-alwp-of-the-ebmt-study
#5
Salyka Sengsayadeth, Myriam Labopin, Ariane Boumendil, Finke Jürgen, Ganser Arnold, Stelljes Matthias, Ehninger Gerhard, Beelen Dietrich, Niederwieser Dietger, Blaise Didier, Dreger Peter, Ghulam Mufti, Chevallier Patrice, Audrey Mailhol, Katie S Gatwood, Norbert Gorin, Jordi Esteve, Fabio Ciceri, Frederic Baron, Christoph Schmid, Sebastian Giebel, Mohamad Mohty, Bipin N Savani, Arnon Nagler
Secondary acute myeloid leukemia (sAML) has been associated with inferior outcomes compared to de novo AML. Little is known about patient risk factors and outcomes in sAML after allogeneic hematopoietic stem cell transplantation (HCT), thus this large systemic analysis of the EBMT registry was performed. This study included 4997 patients with sAML who received HCT from 2000-2016. In univariate analysis, the 2-year cumulative incidence of chronic graft versus host disease (GVHD), relapse (RI), and non-relapse mortality (NRM) were 33...
April 17, 2018: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/29673308/withdrawn-allogeneic-stem-cell-transplantation-in-fanconi-anemia-and-other-inherited-bone-marrow-failure-disorders
#6
(no author information available yet)
Withdrawn by the publisher.
April 19, 2018: Current Drug Targets
https://www.readbyqxmd.com/read/29670622/immune-reconstitution-after-autologous-hematopoietic-stem-cell-transplantation-in-crohn-s-disease-current-status-and-future-directions-a-review-on-behalf-of-the-ebmt-autoimmune-diseases-working-party-and-the-autologous-stem-cell-transplantation-in-refractory
#7
REVIEW
Alan Graham Pockley, James O Lindsay, Gemma A Foulds, Sergio Rutella, John G Gribben, Tobias Alexander, John A Snowden
Patients with treatment refractory Crohn's disease (CD) suffer debilitating symptoms, poor quality of life, and reduced work productivity. Surgery to resect inflamed and fibrotic intestine may mandate creation of a stoma and is often declined by patients. Such patients continue to be exposed to medical therapy that is ineffective, often expensive and still associated with a burden of adverse effects. Over the last two decades, autologous hematopoietic stem cell transplantation (auto-HSCT) has emerged as a promising treatment option for patients with severe autoimmune diseases (ADs)...
2018: Frontiers in Immunology
https://www.readbyqxmd.com/read/29661208/unmanipulated-haploidentical-in-comparison-with-matched-unrelated-donor-stem-cell-transplantation-in-patients-60-years-and-older-with-acute-myeloid-leukemia-a-comparative-study-on-behalf-of-the-alwp-of-the-ebmt
#8
Nicole Santoro, Myriam Labopin, Federica Giannotti, Gerard Ehninger, Dietger Niederwieser, Arne Brecht, Matthias Stelljes, Nicolaus Kröger, Herman Einsele, Matthias Eder, Michael Hallek, Bertram Glass, Jürgen Finke, Fabio Ciceri, Mohamad Mohty, Annalisa Ruggeri, Arnon Nagler
BACKGROUND: Acute myeloid leukemia (AML) is both more common and with more biologically aggressive phenotype in the elderly. Allogenic stem cell transplantation (allo-SCT) is the best treatment option in fit patients. Either HLA-matched unrelated donor (MUD) or haploidentical (Haplo) donor are possible alternative for patients in need. METHODS: We retrospectively compared non-T-cell-depleted Haplo (n = 250) to 10/10 MUD (n = 2589) in AML patients ≥ 60 years...
April 16, 2018: Journal of Hematology & Oncology
https://www.readbyqxmd.com/read/29644709/optimizing-the-pretransplant-regimen-for-autologous-stem-cell-transplantation-in-acute-myelogenous-leukemia-better-outcomes-with-busulfan-and-melphalan-compared-with-busulfan-and-cyclophosphamide-in-high-risk-patients-autografted-in-first-complete-remission
#9
Norbert Claude Gorin, Myriam Labopin, Didier Blaise, Pierre-Yves Dumas, Thomas Pabst, Silvia Maria Trisolini, William Arcese, Mohamed Houhou, Mohamad Mohty, Arnon Nagler
Autologous stem cell transplantation (ASCT) remains a clinical option to consolidate some adult patients with acute myelogenous leukemia (AML) in first complete remission (CR1). In a small cohort of patients, we have previously shown better outcomes following Busulfan and Melphalan (BUMEL) over Busulfan and Cyclophosphamide (BUCY). To identify the subpopulations that might get the highest benefit with BUMEL, we designed a larger study. All adult patients with primary AML and available cytogenetics, autografted from January 2000 to December 2016 in CR1, were included: 1137 patients received BUCY and 512 BUMEL...
April 12, 2018: American Journal of Hematology
https://www.readbyqxmd.com/read/29623467/allogeneic-haematopoietic-cell-transplantation-offers-the-chance-of-cure-for-patients-with-transformed-follicular-lymphoma
#10
Frank Heinzelmann, Wolfgang Bethge, Dietrich Wilhelm Beelen, Matthias Stelljes, Peter Dreger, Marianne Engelhard, Jürgen Finke, Nikolaus Kröger, Ernst Holler, Martin Bornhäuser, Annerose Müller, Imme Haubitz, Hellmut Ottinger
PURPOSE: In patients with follicular lymphoma, secondary transformation to aggressive lymphoma (tFL) implies a poor prognosis. In principle, allogeneic haematopoietic cell transplantation (allo-HCT) offers a chance of cure for tFL but is rarely practiced. Aim of this retrospective multicenter study was to define the actual significance of allo-HCT in treatment of tFL. METHODS: The database of the German Registry for Stem Cell Transplantation (DRST) was screened for patients who underwent allo-HCT for tFL 1998-2008...
April 5, 2018: Journal of Cancer Research and Clinical Oncology
https://www.readbyqxmd.com/read/29603136/anti-thymocyte-globulin-improves-survival-free-from-relapse-and-graft-versus-host-disease-after-allogeneic-peripheral-blood-stem-cell-transplantation-in-patients-with-philadelphia-negative-acute-lymphoblastic-leukemia-an-analysis-by-the-acute-leukemia-working
#11
Tomasz Czerw, Myriam Labopin, Sebastian Giebel, Gérard Socié, Liisa Volin, Nathalie Fegueux, Tamás Masszi, Didier Blaise, Sridhar Chaganti, Jan J Cornelissen, Jakob Passweg, Johan Maertens, Maija Itälä-Remes, Depei Wu, Mohamad Mohty, Arnon Nagler
BACKGROUND: Mobilized peripheral blood stem cells are currently the predominant source of grafts for allogeneic transplantation (allogeneic peripheral blood stem cell transplantation [allo-PBSCT]), although, in comparison with bone marrow, their use is associated with an increased risk of chronic graft-versus-host disease (cGVHD). Attempts to reduce the incidence of cGVHD include the addition of anti-thymocyte globulin (ATG) to the pretransplant conditioning regimen. METHODS: The goal of this retrospective study was to analyze the effect of ATG on allo-PBSCT outcomes for adults with Philadelphia-negative acute lymphoblastic leukemia (Ph-neg ALL)...
March 30, 2018: Cancer
https://www.readbyqxmd.com/read/29574915/cyclophosphamide-versus-etoposide-in-combination-with-total-body-irradiation-as-conditioning-regimen-for-adult-patients-with-ph-negative-acute-lymphoblastic-leukemia-undergoing-allogeneic-stem-cell-transplant-on-behalf-of-the-alwp-of-the-ebmt
#12
Anna Czyz, Myriam Labopin, Sebastian Giebel, Gerard Socié, Jane Apperley, Liisa Volin, Péter Reményi, Ibrahim Yakoub-Agha, Kim Orchard, Mauricette Michallet, Gernot Stuhler, Sridhar Chaganti, Martin Murray, Mahmoud Aljurf, Adrian Bloor, Jacob Passweg, Jürgen Finke, Mohamad Mohty, Arnon Nagler
Allogeneic hematopoietic cell transplantation (alloHCT) with myeloablative conditioning based on total body irradiation (TBI) is widely used for the treatment of adults with acute lymphoblastic leukemia (ALL). TBI is most frequently administered in combination with either cyclophosphamide (Cy/TBI) or etoposide (Vp/TBI). The goal of this study was to retrospectively compare these two regimens. Adult patients with Ph-negative ALL treated with alloHCT in first or second complete remission who received Cy/TBI (n=1346) or Vp/TBI (n=152) conditioning were included in the analysis...
March 25, 2018: American Journal of Hematology
https://www.readbyqxmd.com/read/29548831/second-hematopoietic-stem-cell-transplantation-for-post-transplantation-relapsed-acute-leukemia-in-children-a-retrospective-ebmt-pdwp-study
#13
Isaac Yaniv, Aviva C Krauss, Eric Beohou, Arnaud Dalissier, Selim Corbacioglu, Marco Zecca, Boris V Afanasyev, Massimo Berger, Miguel Angel Diaz, Krzysztof Kalwak, Petr Sedlacek, Stefania Varotto, Christina Peters, Peter Bader
Outcome data were collected from the European Society for Blood and Marrow Transplantation registry on 373 children from 120 centers with relapsed leukemia (214 with acute lymphoblastic leukemia [ALL] and 159 with acute myelogenous leukemia [AML]) who underwent second allogeneic hematopoietic stem cell transplantation (HSCT) between 2004 and 2013. Overall survival (OS) was 38% at 2 years and 29% at 5 years, and leukemia-free survival (LFS) was 30% at 2 years and 25% at 5 years. Median follow-up after second HSCT was 36...
March 13, 2018: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/29544522/post-transplant-cyclophosphamide-for-graft-versus-host-disease-prophylaxis-in-hla-matched-sibling-or-matched-unrelated-donor-transplant-for-patients-with-acute-leukemia-on-behalf-of-alwp-ebmt
#14
Annalisa Ruggeri, Myriam Labopin, Andrea Bacigalupo, Boris Afanasyev, Jan J Cornelissen, Ahmet Elmaagacli, Maija Itälä-Remes, Didier Blaise, Ellen Meijer, Yener Koc, Noel Milpied, Harry C Schouten, Nicolaus Kroeger, Mohamad Mohty, Arnon Nagler
BACKGROUND: Experience using post-transplant cyclophosphamide (PT-Cy) as graft-versus-host disease (GVHD) prophylaxis in allogeneic stem cell transplantation (HSCT) from matched sibling donors (MSD) or unrelated donors (UD) is limited and with controversial results. The study aim was to evaluate PT-Cy as GVHD prophylaxis post-HSCT from MSD and UD transplants. We analyzed 423 patients with acute leukemia who received PT-Cy alone or in combination with other immunosuppressive (IS) drugs as GVHD prophylaxis...
March 15, 2018: Journal of Hematology & Oncology
https://www.readbyqxmd.com/read/29540849/is-the-use-of-unrelated-donor-transplantation-leveling-off-in-europe-the-2016-european-society-for-blood-and-marrow-transplant-activity-survey-report
#15
Jakob R Passweg, Helen Baldomero, Peter Bader, Grzegorz W Basak, Chiara Bonini, Rafael Duarte, Carlo Dufour, Nicolaus Kröger, Jürgen Kuball, Arjan Lankester, Silvia Montoto, Arnon Nagler, John A Snowden, Jan Styczynski, Mohamad Mohty
Hematopoietic cell transplantation (HCT) is an established procedure for acquired and congenital disorders of the hematopoietic system. In 2016, there was a tendency for continued activity in this field with 43,636 HCT in 39,313 patients [16,507 allogeneic (42%), 22,806 autologous (58%)] reported by 679 centers in 49 countries in 2016. The main indications were myeloid malignancies 9547 (24%; 96% allogeneic), lymphoid malignancies 25,618 (65%; 20% allogeneic), solid tumors 1516 (4%; 2% allogeneic), and non-malignant disorders 2459 (6%; 85% allogeneic)...
March 14, 2018: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/29536560/haploidentical-transplantation-outcomes-for-secondary-acute-myeloid-leukemia-aute-leukemia-working-group-alwp-of-the-european-group-for-blood-and-marrow-transplantation-ebmt-study
#16
Zhuoyan Li, Myriam Labopin, Fabio Ciceri, Didier Blaise, Johanna Tischer, Gerhard Ehninger, M T Van Lint, Yener Koc, Stella Santarone, Edouard Forcade, Luca Castagna, Emmanuelle Polge, Audrey Mailhol, Annalisa Ruggeri, Mohamad Mohty, Bipin N Savani, Arnon Nagler
Secondary acute myeloid leukemia (sAML) traditionally has inferior outcomes compared to de novo AML. Allogeneic hematopoietic cell transplantation (HCT) is the sole potentially curative therapy. This study analyzes the outcomes for unmanipulated haploidentical HCT (haploHCT) for sAML using the European Group for Blood and Marrow Transplantation acute leukemia working group registry. We identified 154 patients with sAML who underwent haploHCT from 2006 to 2016. Median age at HCT was 60 years with time from diagnosis to HCT 5 months...
March 14, 2018: American Journal of Hematology
https://www.readbyqxmd.com/read/29535381/protective-environment-for-hematopoietic-cell-transplant-hsct-recipients-the-infectious-diseases-working-party-ebmt-analysis-of-global-recommendations-on-health-care-facilities
#17
Jan Styczynski, Gloria Tridello, J Peter Donnelly, Simona Iacobelli, Jennifer Hoek, Malgorzata Mikulska, Mahmoud Aljurf, Lidia Gil, Simone Cesaro
International guidelines on protective environment for HSCT recipients proposed a set of 10 global recommendations in 2009 on protective environment (GRPE) concerning hospital room design and ventilation. The EBMT Infectious Diseases Working Party undertook a survey on the status on protective environment for HSCT recipients with the aim of surveying current practices and their agreement with GRPE recommendations. The questionnaire consisted of 37 questions divided into 5 sections about filtration, air changes, maintenance, and the protective environment in rooms and the surrounding unit...
March 13, 2018: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/29515252/variability-of-nutritional-practices-in-peritransplant-period-after-allogeneic-hematopoietic-stem-cell-transplantation-a-survey-by-the-complications-and-quality-of-life-working-party-of-the-ebmt
#18
Zinaida Peric, Stefano Botti, Jacqui Stringer, Joanna Krawczyk, Steffie van der Werf, Anja van Biezen, Mahmoud Aljurf, John Murray, Sarah Liptrott, Diana M Greenfield, Rafael F Duarte, Tapani Ruutu, Grzegorz W Basak
Recommendations on screening and nutritional support for patients undergoing hematopoietic stem cell transplantation (HSCT) have been presented by international nutritional societies, but nutritional practices remain poorly standardized. Following the general policy of the European Society for Blood and Marrow Transplantation (EBMT) to standardize transplantation procedures, the Complications and Quality of Life Working Party and Nursing Research Group carried out a survey among all EBMT centers about their current nutritional practices...
March 7, 2018: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/29498106/t-cell-replete-haploidentical-stem-cell-transplantation-attenuates-the-prognostic-impact-of-flt3-itd-in-acute-myeloid-leukemia-a-report-from-the-acute-leukemia-working-party-of-the-european-society-for-blood-and-marrow-transplantation
#19
Jonathan Canaani, Myriam Labopin, Xiao-Jun Huang, William Arcese, Fabio Ciceri, Didier Blaise, Giuseppe Irrera, Lucia Lopez Corral, Benedetto Bruno, Stella Santarone, Maria Teresa Van Lint, Antonin Vitek, Jordi Esteve, Mohamad Mohty, Arnon Nagler
Acute myeloid leukemia (AML) patients harboring the FLT3-ITD mutation are considered a high risk patient subset preferentially allocated for allogeneic stem cell transplantation in first remission. Whether FLT3-ITD retains a prognostic role in haploidentical stem cell transplantation (haplo-SCT) is unknown. To analyze the prognostic impact of FLT3-ITD in haplo-SCT, we performed a retrospective analysis of the multicenter registry of the acute leukemia working party of the European Society for Blood and Marrow Transplantation...
March 2, 2018: American Journal of Hematology
https://www.readbyqxmd.com/read/29481599/incidence-risk-factors-and-long-term-outcome-of-acute-leukemia-patients-with-early-candidemia-after-allogeneic-stem-cell-transplantation-a-study-by-the-acute-leukemia-and-infectious-diseases-working-parties-of-ebmt
#20
Simone Cesaro, Gloria Tridello, Nicole Blijlevens, Per Ljungman, Charles Craddock, Mauricette Michallet, Alexander Martin, John A Snowden, Mohamad Mohty, Johan Maertens, Jacob Passweg, Eefke Petersen, Anne Nihtinen, Cecilia Isaksson, Noel Milpied, Pierre-Simon Rohlich, Eric Deconinck, Charles Crawley, Marie-Pierre Ledoux, Jennifer Hoek, Arnon Nagler, Jan Styczynski
Objectives: To assess the incidence of, and risk factors for, Candida infection in the first 100 days after allogeneic hematopoietic stem cell transplantation (HSCT) and the impact on long-term survival. Methods: outcome analysis of 28,542 acute leukemia patients who underwent HSCT from 2000 to 2012: 347 with candidemia by day +100, and 28,195 without candidemia or any other type of Candida infection. Results: The incidence of candidemia by day +100 was 1...
February 22, 2018: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
keyword
keyword
115198
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"